Literature DB >> 17706171

Multidisciplinary management of special melanoma situations: oligometastatic disease and bulky nodal sites.

Amod A Sarnaik1, Jonathan S Zager, Vernon K Sondak.   

Abstract

Potentially resectable, advanced stage melanoma in the form of extensive palpable adenopathy or limited systemic metastases presents a significant challenge but also offers the prospect of long-term disease control. Although surgical resection is the mainstay of therapy, involvement of a multidisciplinary team is required for optimal management of these special situations. These patients need to be evaluated preoperatively by the team, discussed at a multidisciplinary conference, and treated by experienced physicians with access to the full spectrum of modern surgical and oncologic therapy. Surgical resection is generally extensive and may require en bloc resection of important anatomic structures. Adjuvant radiation or systemic therapy is required in many patients to help achieve durable regional and systemic control of disease. In addition, novel therapies, such as neoadjuvant chemotherapy, targeted therapies, or investigational intralesional therapies, may ultimately play a role in the management of these difficult clinical situations and require further evaluation, as preliminary studies show some encouraging results.

Entities:  

Mesh:

Year:  2007        PMID: 17706171     DOI: 10.1007/s11912-007-0057-5

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  40 in total

1.  Patterns of recurrence in patients with melanoma after radical lymph node dissection.

Authors:  Nir Nathansohn; Jacob Schachter; Haim Gutman
Journal:  Arch Surg       Date:  2005-12

2.  Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma.

Authors:  C J O'Brien; K Petersen-Schaefer; G N Stevens; P C Bass; P Tew; V J Gebski; J F Thompson; W H McCarthy
Journal:  Head Neck       Date:  1997-10       Impact factor: 3.147

3.  Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses.

Authors:  Stergios J Moschos; Howard D Edington; Stephanie R Land; Uma N Rao; Drazen Jukic; Janice Shipe-Spotloe; John M Kirkwood
Journal:  J Clin Oncol       Date:  2006-07-01       Impact factor: 44.544

Review 4.  Choices in adjuvant therapy of melanoma.

Authors:  David H Lawson
Journal:  Cancer Control       Date:  2005-10       Impact factor: 3.302

5.  Is adjuvant radiotherapy necessary after positive lymph node dissection in head and neck melanomas?

Authors:  P Shen; L A Wanek; D L Morton
Journal:  Ann Surg Oncol       Date:  2000-09       Impact factor: 5.344

6.  Evaluation of toxicity following electrically mediated interleukin-12 gene delivery in a B16 mouse melanoma model.

Authors:  Loree Heller; Kathleen Merkler; Jeffrey Westover; Yolmari Cruz; Domenico Coppola; Kaaron Benson; Adil Daud; Richard Heller
Journal:  Clin Cancer Res       Date:  2006-05-15       Impact factor: 12.531

7.  Patterns of regional lymph node metastases from cutaneous melanomas of the head and neck.

Authors:  J P Shah; D H Kraus; S Dubner; S Sarkar
Journal:  Am J Surg       Date:  1991-10       Impact factor: 2.565

8.  Evaluation of 107 therapeutic and elective parotidectomies for cutaneous melanoma.

Authors:  C J O'Brien; K Petersen-Schafer; T Papadopoulos; V Malka
Journal:  Am J Surg       Date:  1994-11       Impact factor: 2.565

Review 9.  Controversies in the management of metastatic melanoma to regional lymphatic basins.

Authors:  Lloyd A Mack; J Gregory McKinnon
Journal:  J Surg Oncol       Date:  2004-07-01       Impact factor: 3.454

10.  Ten-year follow-up results of a randomised controlled study comparing level-I vs level-III axillary lymph node dissection for primary breast cancer.

Authors:  H Kodama; Y Nio; C Iguchi; N Kan
Journal:  Br J Cancer       Date:  2006-10-09       Impact factor: 7.640

View more
  5 in total

Review 1.  How anti-PD1 treatments are changing the management of melanoma.

Authors:  Peter Hersey; Hojabr Kakavand; James Wilmott; Andre van der Westhuizen; Stuart Gallagher; Kavitha Gowrishankar; Richard Scolyer
Journal:  Melanoma Manag       Date:  2014-12-04

2.  Surgical resection for bulky or recurrent axillary metastatic melanoma.

Authors:  Amber L Shada; Dustin M Walters; Shannon N Tierney; Craig L Slingluff
Journal:  J Surg Oncol       Date:  2011-08-08       Impact factor: 3.454

3.  Multidisciplinary management of very advanced stage III and IV melanoma: Proof-of-principle.

Authors:  Haim Gutman; Eytan Ben-Ami; Roni Shapira-Frommer; Jacob Schachter
Journal:  Oncol Lett       Date:  2012-05-11       Impact factor: 2.967

Review 4.  Surgery and radiotherapy in the treatment of cutaneous melanoma.

Authors:  A Testori; P Rutkowski; J Marsden; L Bastholt; V Chiarion-Sileni; A Hauschild; A M M Eggermont
Journal:  Ann Oncol       Date:  2009-08       Impact factor: 32.976

5.  Neoadjuvant therapy for locally advanced melanoma: new strategies with targeted therapies.

Authors:  Michele La Greca; Giuseppe Grasso; Giovanna Antonelli; Alessia Erika Russo; Salvatore Bartolotta; Alessandro D'Angelo; Felice Vito Vitale; Francesco Ferraù
Journal:  Onco Targets Ther       Date:  2014-06-19       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.